www.fdanews.com/articles/190361-robocath-earns-ce-mark-for-robotic-angioplasty-device
Robocath Earns CE Mark for Robotic Angioplasty Device
February 26, 2019
Rouen, France-based Robocath received a CE Mark for its R-One robotic device for treatment of vascular diseases.
The robot complements existing angioplasty methods by giving cardiologists more precision during stenting procedures.
“Building on our CE mark, we expect to finalize a number of strategic distribution partnerships very shortly in high potential geographic areas, with a Europe and Middle East wide launch expected in 2020,” said Philippe Bencteux, the company’s chairman and founder.